Javier Méndez

🆕 Article in press: Dato-DXd combo with durvalumab as 1L treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from the phase Ib/II BEGONIA study annalsofoncology.org/article/S0923-…

#REVIEW 🚨 How does #exercise reduce cancer risk? Zhuang et al. propose that physiological adaptation to aerobic activity reshapes adult stem cell behaviour, limiting transformation and tumour initiation 📖⬇️ dlvr.it/TSfZHT

For readers interested in the evolution of obesity therapy from GLP-1 receptor agonists to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting, here's a comprehensive new review nature.com/articles/s4157…

Dato-DXd now has FDA approval for first-line TNBC👇 TROPION-Breast02

The are likely multiple different resistance mechanisms when cancer progresses after EV/Pembro treatment. Looking forward to @MichalSternsch @MSK_DeptOfMed presenting at #ASCO26 some of the first data with paired biopsies to describe what happens to nectin-4, trop-2, and HER2 post EV/P 🚨abstract: asco.org/abstracts-pres… 🚨

• Real-world patients are usually sicker than clinical trial patients • So logically, real-world OS should be shorter than RCT OS • But sometimes retrospective real-world studies report longer OS • Why? → Selection bias → Immortal-time bias • Patients with early progression, early death, or loss to follow-up may be underrepresented • Better survivors and responders become overrepresented in retrospective analyses • Patients receiving longer treatment must first survive long enough to receive it • So prolonged treatment duration may reflect better survival — not always cause it • RCTs and real-world data are BOTH important • The key is careful interpretation of survival data #Oncology #ClinicalTrials #RealWorldEvidence #MedEd #MVOnco

@JESanchez_ESPN @EitanBenezra ¿cuándo estarán en el nuevo estadio 🏟️ Yu’Va @estadioyuva de los @GuerrerosOax ? ¿Vendrán a la inauguración? @alfredoharphelu @isabelgporrua

📣New work from the NeoTRIPaPDL1 trial led by @BianchiniGP out now in @Annals_Oncology! We profiled tumor gene expression before AND during neoadjuvant chemo ± atezolizumab (ICI) in TNBC to find predictors of pCR: doi.org/10.1016/j.anno… Key findings👇 #TNBC #immunotherapy

Extrachromosomal DNA (ecDNA) drives oncogene amplification, tumour evolution and drug resistance across cancers. This Review in the May issue discusses the translation of ecDNA-targeted therapeutic approaches from bench to bedside nature.com/articles/s4157… rdcu.be/fjMqd

❓Are we approaching a future where some HER2+ breast cancer brain metastases may be managed WITHOUT upfront WBRT? 🧠 CNS metastases have long been the Achilles’ heel of HER2+ breast cancer. But this comprehensive new review highlights how modern HER2-targeted therapies are rapidly reshaping outcomes, even in active brain metastases and leptomeningeal disease. 🚀 Key takeaways 👇 🔹 T-DXd demonstrated remarkable intracranial activity • IC-ORR ~60-70% across studies • DESTINY-Breast12 showed durable CNS control even in active BMs • Potential paradigm shift toward delaying or avoiding upfront WBRT in selected patients 🔹 Tucatinib-based therapy remains a CNS cornerstone HER2CLIMB confirmed: • 40% reduction in risk of death • 66% reduction in CNS progression • Strong activity in both active and stable brain metastases 🔹 Treatment philosophy is evolving The proposed algorithm increasingly integrates: 🧬 CNS-active systemic therapy 🎯 SRS/SRT 🧠 Selective surgery ⚠️ Reduced reliance on WBRT due to neurocognitive toxicity 🔹 Leptomeningeal disease (LMD) Historically devastating, but newer data with: • T-DXd • Tucatinib-based combinations • Intrathecal trastuzumab are finally showing clinically meaningful survival signals. 🔹 Emerging concept: In selected asymptomatic patients with active CNS disease, highly CNS-active systemic therapy may potentially delay or replace immediate local therapy. A major shift from “brain as sanctuary site” → “brain as treatable disease compartment.” 📖 Comprehensive review + therapeutic algorithm proposal in Cancer Treatment Reviews. #bcsm #BreastCancer #HER2 #NeuroOncology #OncoTwitter #MedTwitter @myesmo @asco @ESMO_Open @OncoAlert

Early-stage HER2+ breast cancer algorithm from @PTarantinoMD: myopenmedicine.com/algorithms/ear…

Nivolumab in Upper GI Cancers — 4 Trials Every Oncologist Should Remember 🔹 CheckMate 648 → 1L metastatic ESCC 🔹 ATTRACTION-3 → 2L ESCC after platinum 🔹 CheckMate 577 → Adjuvant after CRT + surgery with residual disease 🔹 CheckMate 649 → 1L metastatic gastric/GEJ adenocarcinoma Simple way to remember the evolving role of nivolumab across the upper GI disease continuum — from frontline metastatic disease to adjuvant therapy. The recurring theme across these trials: 👉 durable survival benefit 👉 immunotherapy survival tail 👉 strongest gains in biomarker-enriched populations, but meaningful real-world applicability #MVOnco #Oncology #ESCC #GastricCancer #Immunotherapy #Nivolumab #MedEd #GIOncology

Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study Full text👇 annalsofoncology.org/article/S0923-…

A major 2026 meta-analysis by involving 15,000+ premenopausal women confirmed that ovarian function suppression (OFS) significantly reduces recurrence and breast cancer mortality in ER+ early breast cancer. • Recurrence ↓ 21% • Distant recurrence ↓ 2% • Breast cancer mortality ↓ 26% in younger women #BreastCancer #ERpositive #Oncology #OFS #Tamoxifen #ESMO #BreastOncology @Larvol @OncoAlert

As a medical oncologist, this is one of the most disturbing breast cancer papers I have read recently. Despite all advances in screening, awareness, and treatment, the incidence of de novo Stage IV breast cancer continues to rise. Even younger patients and men showed increasing rates! @Larvol @OncoDailyIO @OncoAlert #breastcancer #cancer @PTarantinoMD

NEW content online! Mesenchymal stromal/stem cells in tumour initiation, progression and therapy dlvr.it/TSdZwC

🌸 THE 10 MOST IMPORTANT BREAST CANCER TRIALS OF #ASCO26 Chicago is loaded this year. From ctDNA-guided endocrine switching to frontline ADCs and next-gen HER2 platforms, these are the studies most likely to shape breast oncology practice 👇 🩷 HR+ / HER2- DISEASE 1️⃣ persevERA BC (LBA1006) Giredestrant + palbociclib vs letrozole + palbociclib in 1L metastatic disease Despite missing the primary PFS endpoint, biomarker/subset analyses may define where oral SERDs still fit. 2️⃣ SERENA-6 (LBA1007) Camizestrant for emergent ESR1 mutations detected via ctDNA BEFORE radiographic progression Possibly the biggest ctDNA-guided endocrine strategy discussion of the meeting. 3️⃣ VIKTORIA-1 Gedatolisib + fulvestrant ± palbociclib after AI + CDK4/6i progression Huge unmet-need population. Post-CDK4/6 sequencing remains one of the biggest HR+ questions. 4️⃣ lidERA BC (Abstract 502) Adjuvant giredestrant in early ER+/HER2- disease Moving oral SERDs into curative-intent therapy. 5️⃣ FOURLIGHT-2 (Abstract 1042) Next-gen CDK4-selective inhibition with atirmociclib + letrozole Can we reduce neutropenia while preserving efficacy? 🔥 TNBC & ADC ERA 6️⃣ ASCENT-04 (LBA1000) Sacituzumab govitecan + pembrolizumab vs chemo + pembrolizumab in PD-L1+ mTNBC Could ADC + IO combinations become the frontline standard? 7️⃣ TROPION-Breast02 Dato-DXd vs chemotherapy in metastatic TNBC A major test of the “ADC-first” paradigm. 🎯 HER2+ & NEXT-GEN NEOADJUVANT PLATFORMS 8️⃣ KN026-004 (LBA660) Novel biparatopic HER2 antibody vs classic CLEOPATRA-style therapy Watch the pCR data carefully. 9️⃣ I-SPY 2.2 (LBA514) Rilvegostomig + T-DXd in high-risk HER2-negative disease IO + ADC combinations continue moving earlier. 🔟 DESTINY-Breast05 Update Long-term outcomes for T-DXd vs T-DM1 in residual HER2+ disease Which breast abstract are you watching most closely? #BCSM #OncoTwitter #ASCO26 #BreastCancer #MedEd @asco @myesmo @esmo_open @OncoAlert @OncBrothers

The Arsenal. Your Premier League champions.

Seeing this level of discordance even among HER2 3+ cases is surprising. Pathologists, please don’t get mad🙂 but digital pathology and AI support in HER2 ( and the others🫣) assessment are starting to feel like a real necessity rather than an option. aacrjournals.org/clincancerres/…

Realizing the potential of agonistic antibody immunotherapy nature.com/articles/s4157… rdcu.be/fjzZk This new Review discusses progress with agonist antibodies to treat autoimmune diseases and cancer, as well as approaches to addressing challenges in their development